"Drug Labeling" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.
| Descriptor ID |
D004348
|
| MeSH Number(s) |
E05.916.310 J01.576.655.750.321.400 J01.576.761.300.400
|
| Concept/Terms |
Drug Labeling- Drug Labeling
- Labeling, Drug
- Drug Labelling
- Labelling, Drug
- Package Inserts, Drug
- Drug Package Insert
- Drug Package Inserts
- Insert, Drug Package
- Inserts, Drug Package
- Package Insert, Drug
- Product Labeling, Drug
- Drug Product Labeling
- Labeling, Drug Product
Black Box Warning- Black Box Warning
- Black Box Warnings
- Box Warning, Black
- Box Warnings, Black
- Warning, Black Box
- Warnings, Black Box
- Boxed Warning
- Boxed Warnings
- Warning, Boxed
- Warnings, Boxed
|
Below are MeSH descriptors whose meaning is more general than "Drug Labeling".
Below are MeSH descriptors whose meaning is more specific than "Drug Labeling".
This graph shows the total number of publications written about "Drug Labeling" by people in this website by year, and whether "Drug Labeling" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 0 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Labeling" by people in Profiles.
-
Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. JAMA Cardiol. 2021 12 01; 6(12):1415-1423.
-
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 30; 70(17):651-656.
-
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 10 11; 134(15):1122-1124.
-
Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors. Clin Ther. 2015 Jun 01; 37(6):1280-91.
-
Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study. BMJ. 2014 Jun 18; 348:g3596.
-
National antidepressant prescribing in children and adolescents with mental health disorders after an FDA boxed warning. Res Social Adm Pharm. 2014 Sep-Oct; 10(5):781-90.
-
A survey of adult awareness and use of medicine containing acetaminophen. Pharmacoepidemiol Drug Saf. 2013 Mar; 22(3):229-40.
-
Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy. J Child Adolesc Psychopharmacol. 2012 Feb; 22(1):5-10.
-
Baseline and follow-up laboratory monitoring of cardiovascular medications. Ann Pharmacother. 2011 Sep; 45(9):1077-84.
-
Communicating non-steroidal anti-inflammatory drug risks: verbal counseling, written medicine information, and patients' risk awareness. Patient Educ Couns. 2011 Jun; 83(3):391-7.